Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ESPERION THERAPEUTICS, INC.

(ESPR)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/18/2022 01/19/2022 01/20/2022 01/21/2022 01/24/2022 Date
3.725(c) 3.73(c) 3.77(c) 3.78(c) 4.01(c) Last
1 109 194 1 305 073 937 930 1 482 817 1 464 574 Volume
-5.22% +0.13% +1.07% +0.27% +6.08% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 78,1 M - -
Net income 2021 -290 M - -
Net Debt 2021 95,1 M - -
P/E ratio 2021 -0,39x
Yield 2021 -
Sales 2022 78,1 M - -
Net income 2022 -204 M - -
Net Debt 2022 252 M - -
P/E ratio 2022 -1,01x
Yield 2022 -
Capitalization 245 M 245 M -
EV / Sales 2021 4,36x
EV / Sales 2022 6,37x
Nbr of Employees -
Free-Float -
More Financials
Company
Esperion Therapeutics, Inc. is a lipid management company. The Company is a pharmaceutical company focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its bempedoic acid and the bempedoic acid / ezetimibe combination tablets are oral, once-daily, non-statin, LDL-C lowering medicines for patients with... 
Sector
Pharmaceuticals
Calendar
02/22Earnings Release
More about the company
Ratings of Esperion Therapeutics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about ESPERION THERAPEUTICS, INC.
01/14Credit Suisse Lowers Esperion Therapeutics' PT to $6 from $8 After Adjusting Near-Term ..
MT
01/11ESPERION THERAPEUTICS : Provides Preliminary Fourth Quarter 2021 Financial Results and CLE..
PU
01/11Esperion Provides Preliminary Fourth Quarter 2021 Financial Results and CLEAR Outcomes ..
AQ
01/11Esperion Therapeutics, Inc. Provides Earnings Results for the Fourth Quarter of 2021
CI
01/06Esperion to Participate in Upcoming Virtual J.P. Morgan 40th Annual Healthcare Conferen..
GL
01/06Esperion to Participate in Upcoming Virtual J.P. Morgan 40th Annual Healthcare Conferen..
GL
01/04ESPERION THERAPEUTICS : Appoints Benjamin O. Looker as General Counsel - Form 8-K
PU
01/04ESPERION THERAPEUTICS, INC. : Change in Directors or Principal Officers, Regulation FD Dis..
AQ
01/04Esperion Appoints Benjamin O. Looker as General Counsel
GL
01/04Esperion Appoints Benjamin O. Looker as General Counsel
GL
01/04Esperion Appoints Benjamin O. Looker as General Counsel
CI
2021ESPERION THERAPEUTICS, INC.(NASDAQGM : ESPR) added to S&P Pharmaceuticals Select Industry ..
CI
2021Needham Adjusts Esperion Therapeutics' Price Target to $12 from $20, Keeps Buy Rating
MT
2021Esperion Therapeutics Closes $225 Million Common Stock Offering
MT
2021ESPERION THERAPEUTICS : Announces Proposed Public Offering - Form 8-K
PU
More news
News in other languages on ESPERION THERAPEUTICS, INC.
01/11Esperion Therapeutics, Inc. présente ses résultats pour le quatrième trimestre 2021
01/04Esperion nomme Benjamin O. Looker au poste de conseiller général
2021Esperion Therapeutics conclut l'offre d'actions ordinaires pour un montant de 225 milli..
2021Les actions du secteur de la santé à la baisse avant le week-end
2021Les actions du secteur de la santé sont en baisse mais surperforment la plupart des sec..
More news
Analyst Recommendations on ESPERION THERAPEUTICS, INC.
More recommendations
Chart ESPERION THERAPEUTICS, INC.
Duration : Period :
Esperion Therapeutics, Inc. Technical Analysis Chart | ESPR | US29664W1053 | MarketScreener
Technical analysis trends ESPERION THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 11
Last Close Price 4,01 $
Average target price 12,09 $
Spread / Average Target 202%
EPS Revisions
Managers and Directors
Sheldon L. Koenig President, Chief Executive Officer & Director
Richard B. Bartram Chief Financial Officer
William J. Sasiela Senior Vice President-Clinical Development
Ken Fiorelli Chief Technical Operations Officer
JoAnne Micale Foody Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
ESPERION THERAPEUTICS, INC.-19.80%231
JOHNSON & JOHNSON-3.62%434 036
ROCHE HOLDING AG-4.87%319 830
PFIZER, INC.-10.60%296 303
ABBVIE INC.-2.53%233 325
ELI LILLY AND COMPANY-12.00%220 356